-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Policies and Regulations] On August 9, the Ministry of Industry and Information Technology, the National Health and Health Commission, the National Medical Insurance Administration, and the State Food and Drug Administration jointly issued the "Regulations on Strengthening the Monitoring of the Production and Reserve of Selected Drugs in the Centralized Procurement of Drugs in Shortage and National Organizations" Circular, deploying and strengthening the monitoring of production and storage of drugs in shortage and selected drugs in centralized procurement of drugs organized by the state
.
The "Notice" will monitor 1,236 drug shortages and production enterprises, and 783 nationally organized centralized procurement of selected varieties and production enterprises
.
At the same time, it is also required that before the 10th of each month, the above-mentioned 1,236 manufacturers of drugs in shortage and 783 manufacturers of selected drugs for centralized procurement need to fill in relevant monitoring information through the "Monitoring and Early Warning Platform for Production and Supply of Shortage Drugs"
.
The industry believes that the four departments will directly name nearly 2,000 pharmaceutical and related enterprises this time, which will bring warning significance to a large number of enterprises
.
In a way, this is a sufficient advance of monitoring to ensure supply from the production stage of the drug
.
In fact, relevant departments in China have always attached great importance to the problem of drug shortage.
In order to solve the problem of drug shortage, a series of documents and regulations have been issued in recent years
.
In January of this year, the "14th Five-Year Plan for the Development of Pharmaceutical Industry" jointly issued by the Ministry of Industry and Information Technology, the National Development and Reform Commission and other nine departments proposed that it is necessary to enhance the supply guarantee capability of drugs that are prone to shortage, and dynamically adjust the national list of drugs in short supply and the key points of clinically necessary drugs that are prone to shortage.
Monitoring list, strengthen the production and supply chain monitoring and early warning of drugs that are prone to shortage, and establish a supply and demand docking platform for drugs that are prone to shortage
.
In 2021, the General Office of the State Council will issue the "14th Five-Year Plan for National Medical Insurance"
.
Among them, it is proposed to improve the monitoring, early warning and grading response system for drugs in shortage, strengthen the enforcement of illegal acts such as monopoly of raw materials, and further ensure the supply and price of drugs in shortage
.
In November, the State Food and Drug Administration also developed and constructed an information collection module for the production and supply of shortage drugs and discontinuation reports in the drug information collection platform
.
It is worth mentioning that under the guidance of national policies, all localities are also taking active actions to strengthen the supervision and safeguard measures for drugs in short supply and those that are prone to shortage
.
It is reported that on May 5 this year, the Guizhou Provincial Health Commission and other 14 departments jointly issued the "The Fourth Batch of Shortage Drug List in Guizhou Province and the Second Batch of Clinically Necessary Drugs and the Key Monitoring List of Shortage Drugs"
.
Judging from the current policies that have been introduced in China, these regulations and policies are further ensuring the supply of medicines in short supply in China, and providing more thoughtful guarantees for the quality and safety of medicines and the demand for medicines of the people
.
However, at the same time, industry insiders also pointed out that the reasons for the shortage of medicines include many aspects, such as the failure of the standard or the scrapped standard of medicines, and the lack of supply by enterprises; the shortage of raw materials and the monopoly of raw materials; the adjustment and transformation of the production line of enterprises, the lack of production capacity; Enterprises are unwilling to produce; price-limited transactions, enterprises are unwilling to supply; clinical dosage is small, enterprises are unwilling to supply,
etc.
Therefore, China still needs to further improve the R&D capacity and generic production capacity of drugs, and form a more perfect supply guarantee system for the shortage of drugs, so as to fundamentally solve the problem of drug shortage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The "Notice" will monitor 1,236 drug shortages and production enterprises, and 783 nationally organized centralized procurement of selected varieties and production enterprises
.
At the same time, it is also required that before the 10th of each month, the above-mentioned 1,236 manufacturers of drugs in shortage and 783 manufacturers of selected drugs for centralized procurement need to fill in relevant monitoring information through the "Monitoring and Early Warning Platform for Production and Supply of Shortage Drugs"
.
The industry believes that the four departments will directly name nearly 2,000 pharmaceutical and related enterprises this time, which will bring warning significance to a large number of enterprises
.
In a way, this is a sufficient advance of monitoring to ensure supply from the production stage of the drug
.
In fact, relevant departments in China have always attached great importance to the problem of drug shortage.
In order to solve the problem of drug shortage, a series of documents and regulations have been issued in recent years
.
In January of this year, the "14th Five-Year Plan for the Development of Pharmaceutical Industry" jointly issued by the Ministry of Industry and Information Technology, the National Development and Reform Commission and other nine departments proposed that it is necessary to enhance the supply guarantee capability of drugs that are prone to shortage, and dynamically adjust the national list of drugs in short supply and the key points of clinically necessary drugs that are prone to shortage.
Monitoring list, strengthen the production and supply chain monitoring and early warning of drugs that are prone to shortage, and establish a supply and demand docking platform for drugs that are prone to shortage
.
In 2021, the General Office of the State Council will issue the "14th Five-Year Plan for National Medical Insurance"
.
Among them, it is proposed to improve the monitoring, early warning and grading response system for drugs in shortage, strengthen the enforcement of illegal acts such as monopoly of raw materials, and further ensure the supply and price of drugs in shortage
.
In November, the State Food and Drug Administration also developed and constructed an information collection module for the production and supply of shortage drugs and discontinuation reports in the drug information collection platform
.
It is worth mentioning that under the guidance of national policies, all localities are also taking active actions to strengthen the supervision and safeguard measures for drugs in short supply and those that are prone to shortage
.
It is reported that on May 5 this year, the Guizhou Provincial Health Commission and other 14 departments jointly issued the "The Fourth Batch of Shortage Drug List in Guizhou Province and the Second Batch of Clinically Necessary Drugs and the Key Monitoring List of Shortage Drugs"
.
Judging from the current policies that have been introduced in China, these regulations and policies are further ensuring the supply of medicines in short supply in China, and providing more thoughtful guarantees for the quality and safety of medicines and the demand for medicines of the people
.
However, at the same time, industry insiders also pointed out that the reasons for the shortage of medicines include many aspects, such as the failure of the standard or the scrapped standard of medicines, and the lack of supply by enterprises; the shortage of raw materials and the monopoly of raw materials; the adjustment and transformation of the production line of enterprises, the lack of production capacity; Enterprises are unwilling to produce; price-limited transactions, enterprises are unwilling to supply; clinical dosage is small, enterprises are unwilling to supply,
etc.
Therefore, China still needs to further improve the R&D capacity and generic production capacity of drugs, and form a more perfect supply guarantee system for the shortage of drugs, so as to fundamentally solve the problem of drug shortage
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
